FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.
What happened
FDA inspected Safrel's drug facility at 178 Ridge Road, Dayton, New Jersey, from January 13 to January 30, 2026. Investigators found no quality unit oversight of the company's suppliers and contract manufacturers, no certificates of analysis for incoming drug products, unlabeled product stored alongside labeled product, and no way to trace which lots went to which customers. FDA reviewed the company's February 22, 2026 response and found it inadequate, in part because it did not assess the impact on drugs already distributed.
What FDA found
The company had no adequate quality unit overseeing the drugs it sells, and its quality duties were not written down or followed.
21 CFR 211.22(a) and 21 CFR 211.22(d)It did not qualify its suppliers and contract manufacturers, had no written quality agreements with them, and did not request or keep certificates of analysis for incoming drug products.
Unlabeled filled product containers were stored in the same area as labeled drug products, and there were no written procedures for receiving, quarantining, storing, and releasing finished drugs.
21 CFR 211.42There were no procedures to work out where each lot of drug product was distributed, which would make a recall impossible to carry out.
FDA could not verify the packaging and labeling done at the site because the company had no records of those operations or of what happened to the materials used, and large rolls of product labels were kept in the office area.
21 CFR 211.42(b)
What FDA wants
FDA tells the company to correct the violations and reply in writing within 15 working days with a full assessment and remediation plan for its quality unit, a review of all suppliers and contract manufacturers, a review of its warehousing, and an assessment of its documentation and lot traceability. FDA also recommends hiring a qualified CGMP consultant.
Who should pay attention
- brand owners that use contract manufacturers and packagers for OTC drugs
- OTC distributors and private-label sellers that release product without in-house manufacturing
- companies setting up supplier qualification and lot traceability programs
This is a summary. Read the original letter on fda.gov.